Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Canatu's reactor business takes steps towards mass production and recurring revenue

By Atte RiikolaAnalyst
Canatu

Translation: Original published in Finnish on 07/14/2025 at 07:44 am EEST

Canatu announced on Friday that it has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and post-processing equipment, which were delivered to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer’s premises and met the stringent technical requirements and specifications defined in the acceptance criteria. According to the company, this confirms the CNT100 SEMI reactor’s readiness for mass production of CNT pellicle membranes.

Canatu's stock, which has been under pressure in recent months, received a significant boost from the news (+16.4%), suggesting that investors have not fully believed in the completion of the approval tests this year. In our view, the news reduces the technological risks associated with Canatu's reactor business, but there are still a few steps to go through before mass production starts at the customer's end.

The next step for the customer is to secure final approval for the finished carbon nanotube pellicle membrane and the entire production line before the pilot and risk mass production starts. This phase would enable the mass production of Canatu's carbon nanotube pellicle membranes, which would generate one-off revenues for the company from technology licensing and recurring revenues as royalties from the sale of carbon nanotube pellicle membranes and reactor consumables. These recurring revenues from the reactor business also form the core of the company's investment case, and we expect strong revenue growth to be weighted towards 2027-2028, when several reactors have been delivered to customers.

In its outlook provided in connection with the financial statements (our update can be found here), Canatu estimates that the approval tests for the first two delivered reactors will be completed during 2025. In this respect, things seem to be progressing according to plan, but as per our previous estimates, the first reactors are unlikely to reach mass production on the customer's end this year. Canatu also expects that any further reactor orders from existing customers will likely depend on the successful completion of the final approval tests of the first two reactors and related equipment. Based on Friday's news, we believe it is slightly more probable that Canatu will announce one or two new reactor orders before the end of the year.

Canatu is a technology company active in deep technology that creates carbon nanotubes (Canatu CNT), related products and manufacturing equipment for the semiconductor, automotive and medical diagnostics industries. The company operates through two business models, firstly using their own reactors to develop and manufacture CNT products. Second, the company sells its CNT reactors and licenses its related technology, allowing customers to produce the products themselves under a limited license.

Read more on company page

Key Estimate Figures2025-06-15

202425e26e
Revenue22.022.835.4
growth-%62.1 %3.7 %55.1 %
EBIT (adj.)-4.8-7.5-4.0
EBIT-% (adj.)-21.9 %-32.8 %-11.4 %
EPS (adj.)-0.01-0.11-0.07
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Market size is certainly not going to be reached anytime soon: https://x.com/dwarkesh_sp/status/2032514120461988204?s=46&t=499WpwaAyJmQ9CLT93iGoA
10 hours ago
by Kroisos Pennonen
1
It looks like there’s about a six-month delay for the start of Canatu’s ramp-up. I suspect the CMD was moved to the end of March so they could...
yesterday
by timontti
16
I don’t know which thread would fit this best, but as many of you know, the Strait of Hormuz is of great importance for Qatar’s helium shipments...
3/11/2026, 11:50 AM
by timontti
15
Micron (DRAM memory manufacturer) has in 2025-2026 deployed its first production line using EUV instead of the former DUV (‘1-gamma production...
3/6/2026, 5:21 PM
by timontti
10
Intel’s CFO reiterated that the company remains aligned with its original roadmap. Under the current plan, 14A is expected to enter risk production...
3/5/2026, 9:51 AM
by timontti
6
A small nuance regarding the pellicle price: In the earnings webcast, Kokkonen spoke about composite pellicle prices ranging between ~$35-50k...
3/4/2026, 12:13 PM
by timontti
7
Exclusive: Tesla to “More Than Double AI6 Production”… Pursuing Additional Orders with Samsung Summary Tesla has been identified as being in...
3/4/2026, 7:54 AM
by timontti
17
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.